CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
构建新型 CD19/CD22 双靶点 CAR-T 细胞以增强抗肿瘤活性
英文原题：Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity.
查看英文原题
Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管B细胞急性淋巴细胞白血病（B-ALL）接受CAR-T 细胞治疗后缓解率很高，但靶抗原丢失导致的复发日益被认为是免疫逃逸的一种机制。我们假设同时靶向CD19和CD22可能改善CAR-T 效果。建立体外和体内白血病模型，观察BiCAR-T、CD19 CAR-T、CD22 CAR-T 和LoopCAR6细胞的抗肿瘤作用。我们发现BiCAR-T 细胞在体外和体内均表现出显著的细胞毒性。CD19/CD22双价CAR为测试同时靶向是否可降低抗原丢失风险提供了机会。
展开英文摘要原文
Despite high remission rates following chimeric antigen receptor T cell (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL), relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape.
We hypothesized that simultaneous targeting of CD19 and CD22 may improve the CAR-T effect. The in vitro and in vivo leukemia model was established, and the anti-tumor effects of BiCAR-T, CD19 CAR-T, CD22 CAR-T, and LoopCAR6 cells were observed.
We found that the BiCAR-T cells showed significant cytotoxicity in vitro and in vivo . The CD19/CD22 bivalent CAR provides an opportunity to test whether simultaneous targeting may reduce the risk of antigen loss.
论文信息
- 作者
- Zeng W、Zhang Q、Zhu Y、Ou R、Peng L、Wang B、Shen H、Liu Z
- 第一作者单位
- National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-targeting Theranostics, Guangxi Medical University, Nanning, China.China
- 通讯作者单位
- Department of Hematology, Guangdong Second Provincial General Hospital, Guangzhou, China.China
- 期刊
- Cancer investigation2022 Mar
- 原文标识
- PubMed 34797742 · DOI 10.1080/07357907.2021.2005798